Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

IFITM3 protects the heart during influenza virus infection.

Kenney AD, McMichael TM, Imas A, Chesarino NM, Zhang L, Dorn LE, Wu Q, Alfaour O, Amari F, Chen M, Zani A, Chemudupati M, Accornero F, Coppola V, Rajaram MVS, Yount JS.

Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18607-18612. doi: 10.1073/pnas.1900784116. Epub 2019 Aug 26.

PMID:
31451661
2.

The mode of mitosis is dramatically modified by deletion of a single nuclear pore complex gene in Aspergillus nidulans.

Chemudupati M, Johns M, Osmani SA.

Fungal Genet Biol. 2019 Sep;130:72-81. doi: 10.1016/j.fgb.2019.04.010. Epub 2019 Apr 23.

PMID:
31026588
3.

From APOBEC to ZAP: Diverse mechanisms used by cellular restriction factors to inhibit virus infections.

Chemudupati M, Kenney AD, Bonifati S, Zani A, McMichael TM, Wu L, Yount JS.

Biochim Biophys Acta Mol Cell Res. 2019 Mar;1866(3):382-394. doi: 10.1016/j.bbamcr.2018.09.012. Epub 2018 Oct 2. Review.

PMID:
30290238
4.

IFITM3 Restricts Human Metapneumovirus Infection.

McMichael TM, Zhang Y, Kenney AD, Zhang L, Zani A, Lu M, Chemudupati M, Li J, Yount JS.

J Infect Dis. 2018 Oct 5;218(10):1582-1591. doi: 10.1093/infdis/jiy361.

5.

The palmitoyltransferase ZDHHC20 enhances interferon-induced transmembrane protein 3 (IFITM3) palmitoylation and antiviral activity.

McMichael TM, Zhang L, Chemudupati M, Hach JC, Kenney AD, Hang HC, Yount JS.

J Biol Chem. 2017 Dec 29;292(52):21517-21526. doi: 10.1074/jbc.M117.800482. Epub 2017 Oct 27.

6.

A balancing act between IFITM3 and IRF3.

McMichael TM, Chemudupati M, Yount JS.

Cell Mol Immunol. 2018 Oct;15(10):873-874. doi: 10.1038/cmi.2017.18. Epub 2017 Apr 24. No abstract available.

7.

A mitotic nuclear envelope tether for Gle1 also impacts nuclear and nucleolar architecture.

Chemudupati M, Osmani AH, Osmani SA.

Mol Biol Cell. 2016 Sep 14. pii: mbc.E16-07-0544. [Epub ahead of print]

8.

Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy.

Butchar JP, Mehta P, Justiniano SE, Guenterberg KD, Kondadasula SV, Mo X, Chemudupati M, Kanneganti TD, Amer A, Muthusamy N, Jarjoura D, Marsh CB, Carson WE 3rd, Byrd JC, Tridandapani S.

Clin Cancer Res. 2010 Apr 1;16(7):2065-75. doi: 10.1158/1078-0432.CCR-09-2591. Epub 2010 Mar 23.

Supplemental Content

Loading ...
Support Center